Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis

Parasitology

Volumn 127, Issue 2, 2003, Pages 107-114

  Srivastava, J K ^a   Misra, A ^a   Sharma, P ^a   Srivastava, B ^a   Naik, S ^b   Dube, A ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Autoclaved L. donovani; Autoclaved L. major; Hamster; Vaccination; Visceral leishmaniasis

Indexed keywords

BCG VACCINE; CONCANAVALIN A; LEISHMANIA VACCINE; NEOSPORIN; PHYTOHEMAGGLUTININ; PROTOZOON ANTIBODY;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCLAVE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HAMSTER; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; SPLEEN BIOPSY; SURVIVAL TIME; VACCINATION; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; BCG VACCINE; CRICETINAE; DISEASE MODELS, ANIMAL; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS, VISCERAL; PROTOZOAN VACCINES; STERILIZATION; SURVIVAL RATE;

ANIMALIA; CRICETINAE; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; MESOCRICETUS; MESOCRICETUS AURATUS; MYCOBACTERIUM BOVIS BCG; PROTOZOA;

EID: 0042355184     PISSN: 00311820     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0031182003003457     Document Type: Article

References (37)

1. AFONSO, L. C., SCHARTON, T. M., VIEIRA, L. Q., WYSOCKA, M., TRINCHIERI, G. & SCOTT, P. (1994). The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263, 235-237.
2. ALEXANDER, J. (1988). Chemotherapy and immune response. In Leishmaniasis: The Current Status and New Strategies for Control: NATO-ASI Series A., Vol. 163 (ed. Hart, D. T.), pp. 839-843. Plenum Press, New York.
3. ARMIJOS, R. X., WEIGEL, M. M., AVILES, H., MALDONADO, R. & RACINES, J. (1998). Field trial of a vaccine against New World Cutaneous leishmaniasis in an at-risk child population. Safety, immunogencity, and efficacy during the first 12 months of follow-up. Journal of Infectious Diseases 177, 1352-1357.
4. BADARO, R., JONES, T. C., CARVALHO, E. M., SAMPAIO, D., REED, S. G., BARRAL, A., TEIXEIRA, R. & JOHNSON, Jr W. D. (1986). New perspectives on a subclinical form of visceral leishmaniasis. Journal of Infectious Diseases 154, 1003-1011.
5. BERGER, B. J. & FAIRLAMB, A. H. (1992). Interaction between immunity and chemotherapy in the treatment of trypanosomiasis and leishmaniasis. Parasitology 105, S71-S78.
6. BRETSCHER, P. A., ISMAIL, N., MENON, J. N., POWAR, C. A., UZONNA, J. & WEI, G. (2001). Vaccination against and treatment of tuberculosis, the leishmaniasis and AIDS: Perspectives from basic immunology and immunity to chronic intracellular infections (Review). Cellular and Molecular Life Sciences 58, 1879-1896.
7. CARVALHO, E. M., BACELLAR, O., BROWNELL, C., REGIS, T., COFFMAN, R. L. & REED, S. G. (1994). Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. Journal of Immunology 152, 5949-5956.
8. CARVALHO, E. M., BADARO, R., REED, S., JONES, T. C. & JOHNSON, W. D. (1985). Absence of gamma-interferon and interleukin-2 production during active visceral leishmaniasis. Journal of Clinical Investigation 76, 2066-2069.
9. CASTES, M., BLACKWELL, J., TRUJILLO, D., FORMICA, S., CABRERA, M., ZORRILLA, G., RODAS, A., CASTELLANOS, P. L. & CONVIT, J. (1994). Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG I. Skin-test reactivity T-cell prolfieration and interferon-γ production. Vaccine 12, 1041-1051.
10. CHOUDHURY, A., GURU, P. Y., SAXENA, R. P., TANDON, A. & SAXENA, K. C. (1990). Enzyme linked immunosorbant assay in diagnosis of kala-azar in Bhadohi (Varanasi) India. Transactions of the Royal Society of Tropical Medicine and Hygiene 84, 363-367.
11. DUBE, A., SHARMA, P., SRIVASTAVA, J. K., MISRA, A. & KATIYAR, J. C. (1998). Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 116, 219-221.
12. DUBE, A., SRIVASTAVA, J. K., SHARMA, P., CHATURVEDI, A., KATIYAR, J. C. & NAIK, S. (1999). Leishmania donovani: cellular and humoral immune responses in Indian langur monkeys Presbytus entellus. Acta Tropica 73, 37-48.
13. FLESCH, I. E., HESS, J. H., HUANG, S., AGUET, M., ROTHE, J., BLUETHMANN, H. & KAUFMANN, S. H. (1995). Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. Journal of Experimental Medicine 181, 1615-1621.
14. FROMMEL, D. & LAGRANGE, P. H. (1989). BCG: A modifier of immune responses to parasites. Parasitology Today 5, 188-189.
15. GICHERU, M. M., OLOBO, J. O., ANJILI, C. O., ORAGO, A. S., MODABBER, F. & SCOTT, P. (2001). Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type-1 immune response but are not protected against challenge infection. Infection and Immunity 69, 245-251.
16. GICHERU, M. M., OLOBO, J. O. & ANJILI, C. O. (1997). Heterologous protection by Leishmania donovani for Leishmania major infection in Vervet Monkey model of the disease. Experimental Parasitology 85, 109-116.
17. GREENBLATT, C. L. (1980). The present and future of vaccination for cutaneous leishmaniasis. In New Developments with Human and Veterinary Vaccines Progress in Clinical and Biological Research 47, (ed. Mizrahi, A., Hertman, I., Klingerg, M. A. & Kohn, A.), pp. 259-285. Alan R Liss, New York, New York.
18. GUPTA, S., SRIVASTAVA, J. K., RAY, S., CHANDRA, R., SRIVASTAVA, V. K. & KATIYAR, J. C. (1993). Evaluation of enzyme linked immunosorbant assay in the diagnosis of kala-azar in Malda district (West Bengal). Indian Journal of Medical Research 97, 242-246.
19. HANDMAN, E. (2001). Leishmaniasis: current status of vaccine development. Clinical Microbiology Review 14, 229-243.
20. HO, M., SINGOK, T. K., LYERLY, W. & SMITH, D. (1982). Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene 76, 741-746.
21. HOWARD, J. G. & LIEW, F. Y. (1984). Mechanisms of acquired immunity in leishmaniasis. Philosophical Transactions of the Royal Society, B 307, 87-98.
22. JHA, T. K., OLLIARO, P., THAKUR, C. P. N., SINGH, I. J., SINGH, N. K. P., AKHOURI, S. & JHA, S. (1998). Randomised controlled trial of aminosidine (paromomycin) vs sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. British Medical Journal 361, 1200-1205.
23. KHALIL, E. A. G., EL-HASSAN, A. M., ZIJLSTRA, E. E., MUKHTAR, M. M., GHALIB, H. W., MUSA, B., IBRAHIM, M. S., KAMIL, A. A., EHSHEIKH, M., BABIKER, A. & MODABBER, F. (2000). Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in Sudan. Lancet 356, 1565-1569.
24. LAGRANDERIE, M. R., BALAZUC, A. M., DERIAUD, E., LECLERC, C. D. & GHEORGHIU, M. (1996). Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infection and Immunity 64, 1-9.
25. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. & RANDALL, R. J. (1951). Protein measurement with folin-phenol reagent. Journal of Biological Chemistry 193, 265-275.
26. MAUEL, J. (2002). Vaccination against leishmania infections. Current Drug Targets-Immune, Endocrine and Metabolic Disorders 2, 201-226.
27. MAYRINK, W., WILLIAMS, P., DACOSTA, C. A., MAGALHAES, P. A., MELO, M. N., DIAS, M., LIMA, A. O., MICHALICK, M. S. M., CARVALHO, E. F., BARROS, G. C., SESSA, P. A. & DE ALENCAR, J. T. A. (1985). An experimental vaccine against American dermal leishmaniasis: experience in the state of Espirito Santo, Brazil. Annals of Tropical Medicine and Parasitology 79, 259-269.
28. MISRA, A., DUBE, A., SHARMA, P., SRIVASTAVA, J. K., SRIVASTAVA, B., KATIYAR, J. C. & NAIK, S. (2001). Successful vaccination against Leishmania donovani infection in Indian langurs using Alum-precipitated autoclaved L. major (ALM) with BCG. Vaccine 19, 3485-3492.
29. MITCHELL, G. F. & HANDMAN, E., (1987). Heterologous protection in murine cutaneous leishmaniasis. Immunology and Cell Biology 65, 387-392.
30. MOMENI, A. Z., JALAYER, T., EMAMJOMEH, M., KHAMESIPOUR, A., ZICKER, F., GHASSEMI, R. L., DOWLATI, Y., SHARIFI, I., AMINJAVAHERI, M., SHAFIEI, A., ALIMOHAMMADIAN, M. H., FESHARKI, R. H., NASSERI, K., GODAL, T., SMITH, P. G. & MODABBER, F. (1998). A randomised, double-blind controlled trial of a killed Leishmania major plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17, 466-472.
31. NURIT, R. & JAFFE, C. L. (1993). Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. Journal of Immunology 150, 2322-2331.
32. REZAI, H. R., ARDEHALI, S. M., ALMIRHAKIMI, G. & KHARAZMI, A. (1978). Immunological features of kala-azar. American Journal of Tropical Medicine and Hygiene 27, 1079-1083.
33. SHARMA, P., ANURADHA, SRIVASTAVA, J. K., GUPTA, H. P. & KATIYAR, J. C. (1998). Immunization against Leishmania donovani: efficacy of Mycobacterium habana in combination with killed promastigotes in hamsters. Current Science 70, 770-773.
34. SUNDAR, S., SINGH, V. P., SHARMA, S., MAKHARIA, M. K. & MURRAY, H. W. (1997). Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis. Journal of Infectious Diseases 176, 1117-1119.
35. THAKUR, C. P. (1993). Kala-azar background paper, Status paper on kala-azar in Bihar. Core Group Discussion on Kala-Azar Control in India. 24-25 September, 1993.
36. VOLLER, A., BIDWELL, D. E. & BARTLETT, A. (1979). The Enzyme-Linked Immunosorbent Assay (ELISA): a Guide with Abstracts of Microplate Application. Fileroline Press, Guernsey, Channel Islands.
37. WHO (1998). Advances in battle against leishmaniasis. TDR News 34, 1-7.